DYNDyne Therapeutics, Inc.

$3B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$470M-40.6% YoY

Gross Profit

-$237M-50.4% margin

Operating Income

-$467M-99.4% margin

Net Income

-$1.4B-300.2% margin

EPS (Diluted)

$-8.71

QoQ Revenue Growth

+158.2%

Cash Flow

Operating Cash Flow

$84M

Free Cash Flow

-$140M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$11.8B

Total Liabilities

$9.9B

Stockholders' Equity

$1.9B

Cash & Equivalents

$365M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$470M	$791M	-40.6%
Gross Profit	-$237M	$208M	-213.9%
Operating Income	-$467M	$34M	-1473.5%
Net Income	-$1.4B	-$182M	-675.3%

DYN Q4 2017 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena